Trials / Completed
CompletedNCT06761703
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
Community Outreach Support and Engagement Using Online Strategies - Decentralized Insights Into Therapy Adoption and Value
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TAP® Micro Select Device (Touch Activated Phlebotomy) | The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood. |
Timeline
- Start date
- 2024-11-14
- Primary completion
- 2025-01-06
- Completion
- 2025-01-06
- First posted
- 2025-01-07
- Last updated
- 2025-01-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06761703. Inclusion in this directory is not an endorsement.